Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease
| Autor: | Wang, Fen, Gordon, Brian A, McDade, Eric, Ringman, John M, Graff-Radford, Neill R, Ghetti, Bernardino, Farlow, Martin R, Sperling, Reisa, Salloway, Steve, Schofield, Peter R, Masters, Colin L, Martins, Ralph N, Ryman, Davis C, Rossor, Martin N, Jucker, Mathias, Danek, Adrian, Förster, Stefan, Lane, Christopher A S, Morris, John C, Benzinger, Tammie L S, Bateman, Randall J, Network, Dominantly Inherited Alzheimer, Ma, Shengmei, Xiong, Chengjie, Hassenstab, Jason, Goate, Alison, Fagan, Anne M, Cairns, Nigel J, Marcus, Daniel S |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Pediatrics psychology [Alzheimer Disease] psychology [Amyloidosis] Apolipoprotein E4 genetics [Alzheimer Disease] Neuropsychological Tests diagnostic imaging [Cognition Disorders] APP protein human Developmental psychology Amyloid beta-Protein Precursor psychology [Brain Diseases] Longitudinal Studies Cognitive decline Episodic memory genetics [Apolipoprotein E4] Brain Diseases Amyloidosis physiopathology [Amyloidosis] Neuropsychology Brain Cognition genetics [Presenilin-1] Middle Aged genetics [Amyloid beta-Protein Precursor] Disease Progression Female diagnostic imaging [Brain Diseases] Alzheimer's disease Psychology Adult medicine.medical_specialty diagnostic imaging [Amyloidosis] genetics [Presenilin-2] physiopathology [Alzheimer Disease] PSEN1 protein human Alzheimer Disease Presenilin-2 medicine Presenilin-1 Dementia Humans ddc:610 Effects of sleep deprivation on cognitive performance Radionuclide Imaging diagnostic imaging [Brain] PSEN2 protein human medicine.disease Cross-Sectional Studies physiopathology [Brain Diseases] Neurology (clinical) Cognition Disorders diagnostic imaging [Alzheimer Disease] Follow-Up Studies |
| Zdroj: | Neurology 85(9), 790-798 (2015). doi:10.1212/WNL.0000000000001903 |
| ISSN: | 1526-632X |
| DOI: | 10.1212/WNL.0000000000001903 |
| Popis: | Objective: To investigate the associations of cerebral amyloidosis with concurrent cognitive performance and with longitudinal cognitive decline in asymptomatic and symptomatic stages of autosomal dominant Alzheimer disease (ADAD). Methods: Two hundred sixty-three participants enrolled in the Dominantly Inherited Alzheimer Network observational study underwent neuropsychological evaluation as well as PET scans with Pittsburgh compound B. One hundred twenty-one participants completed at least 1 follow-up neuropsychological evaluation. Four composite cognitive measures representing global cognition, episodic memory, language, and working memory were generated using z scores from a battery of 13 standard neuropsychological tests. General linear mixed-effects models were used to investigate the relationship between baseline cerebral amyloidosis and baseline cognitive performance and whether baseline cerebral amyloidosis predicts cognitive change over time (mean follow-up 2.32 years ± 0.92, range 0.89–4.19) after controlling for estimated years from expected symptom onset, APOE e4 allelic status, and education. Results: In asymptomatic mutation carriers, amyloid burden was not associated with baseline cognitive functioning but was significantly predictive of longitudinal decline in episodic memory. In symptomatic mutation carriers, cerebral amyloidosis was correlated with worse baseline performance in multiple cognitive composites and predicted greater decline over time in global cognition, working memory, and Mini-Mental State Examination. Conclusions: Cerebral amyloidosis predicts longitudinal episodic memory decline in presymptomatic ADAD and multidomain cognitive decline in symptomatic ADAD. These findings imply that amyloidosis in the brain is an indicator of early cognitive decline and provides a useful outcome measure for early assessment and prevention treatment trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|